OBSERVATIONAL STUDY OF ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) CONVERTING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)

被引：0

作者：

Lunde, Martin ^{[1
]}

Jackson, James ^{[2
]}

Lunacsek, Orsolya ^{[2
]}

Bailey, Robert A. ^{[3
]}

Senbetta, Mekre

McKenzie, R. Scott ^{[3
]}

机构：

[1] Twin Cities Clin Res, Minneapolis, MN USA

[2] Xcenda LLC, Palm Harbor, FL USA

[3] Centocor Ortho Biotech Serv LLC, Horsham, PA USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2011年 / 57卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

176

引用

页码：A60 / A60

页数：1

共 50 条

[21] Real-world epoetin alfa (EPO) and darbepoetin alfa (DARB) dosing and cost considerations in elderly hospital inpatients: Results from a large observational study
Duh, M.
Vekeman, F.
Mckenzie, R. S.
Lefebvre, P.
Watson, S.
Mody, S.
Piech, C. T.
VALUE IN HEALTH, 2007, 10 (03) : A131 - A131
[22] The economic impact of epoetin alfa (EPO) therapy on delaying time to dialysis in elderly patients with chronic kidney disease (CKD)
Lefebvre, P
Duh, M
Mody, S
Bookhart, B
Piech, CT
VALUE IN HEALTH, 2006, 9 (03) : A16 - A17
[23] Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis
Barnett, AI
Crémieux, PY
PHARMACOTHERAPY, 2003, 23 (05): : 690 - 693
[24] Comment on:: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease
Einarson, Thomas
Machado, Marcio
Walker, John
Iskedjian, Michael
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (07) : 1571 - 1573
[25] Extended intervals using epoetin alfa in pre-dialysis patients with chronic kidney disease (CKD) appears to be limited to patients with low dose requirements.
Wish, J
Law, AW
Schulman, KL
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A62 - A62
[26] Darbepoetin alfa maintains mean hemoglobin (Hb) levels in chronic kidney disease (CKD) patients who are erythropoietin (EPO)-naive or are converting from EPO therapy
Hertel, J
Locay, H
Scarlata, D
Jackson, L
Brenner, R
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : A25 - A25
[27] Hemoglobin and hematocrit response for alternate dosing strategies of epoetin alfa in pre-dialysis chronic kidney disease
Sarac, E
Smavatkul, C
Boolchand, V
Gemmel, D
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : A41 - A41
[28] Comment on:: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease -: Reply
Cremieux, Pierre-Yves
Van Audenrode, Marc
Lefebvre, Patrick
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (07) : 1573 - 1574
[29] Exposure-Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis
Doshi, Sameer
Chow, Andrew
Perez Ruixo, Juan Jose
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 75S - 90S
[30] An examination of direct and indirect employer costs associated with epoetin alfa treatment in pre-dialysis chronic kidney disease patients
Bookhart, Brahim K.
Papatheofanis, Frank
Chawla, Namrita
Muser, Erik
Piech, Catherine Tak
AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A31 - A31

← 1 2 3 4 5 →